AN2 Therapeutics Inc., a biopharmaceutical company specializing in novel small molecule therapeutics, will present a poster at the Nontuberculous Mycobacteria Conference from May 27-30, 2025, at Colorado State University. The presentation, scheduled for May 29, will highlight the preclinical activity of epetraborole, a potential oral agent for Mycobacterium abscessus lung disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.